Clinical Trial Update: Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cetuximab and bevacizumab with or without gemcitabine in metastatic pancreatic cancer was terminated, and results were posted in 2009…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Avastin (bevacizumab) (bevacizumab)
• Erbitux (cetuximab) (cetuximab)
• Gemzar (gemcitabine) (gemcitabine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2009-12-04